文献速递艾滋病与性传播感染

HIV-1蛋白酶、Gag和gp41基线替换与PI方案病毒学应答的关联

HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen.
PubMed 文献 · J Antimicrob Chemother · 2019-01-01

发现蛋白酶T4A、S37T及CRF02_AG中的I72M、E21D,Gag的G62D、N315H、Y441S,以及gp41的I270T与病毒学失败相关,而gp41的I4L与病毒学成功相关。

要点

  • 蛋白酶T4A、S37T及CRF02_AG中I72M、E21D与病毒学失败相关。
  • Gag G62D、N315H、Y441S位于切割位点外,与病毒学失败相关。
  • gp41 I270T与失败相关,I4L与成功相关,需表型验证。

核心结论

  • 研究识别出Gag、蛋白酶和gp41多个基线替换可能影响PI方案结局,需表型分析确认其在PI耐药机制中的作用。

研究设计与样本

  • 基线时采用Illumina超深度测序对pol、gag和gp41基因进行测序,并进行监督数据挖掘和结构分析。

主要发现

  • 蛋白酶T4A和S37T与病毒学失败相关(P=0.02和P=0.005)。
  • CRF02_AG序列中I72M和E21D与病毒学失败相关(P均为0.03)。
  • Gag G62D、N315H和Y441S与病毒学失败相关(P=0.005、P=0.007和P=0.0003)。
  • gp41 I270T与病毒学失败相关(P=0.003),I4L与病毒学成功相关(P=0.004)。
  • 上述突变均引起蛋白酶侧链残基构象变化,但Gag突变位于切割位点外。

临床怎么用

  • 临床启动PI方案前可考虑检测这些基线替换以评估病毒学失败风险,但需表型验证后应用。

局限性

  • 需表型分析确认这些替换在PI耐药机制中的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess, at ART initiation, the impact of baseline substitutions in protease, Gag and gp41 regions on the virological response to a first-line PI-based regimen. PATIENTS AND METHODS: One hundred and fifty-four HIV-infected ART-naive patients initiating a PI-based regimen including darunavir (n = 129) or atazanavir (n = 25) were assessed, including 36 experiencing virological failure (VF). Whole pol, gag and gp41 genes were sequenced at ART baseline by ultra-deep sequencing (UDS) using Illumina® technology. Supervised data-mining analyses were performed to identify mutations associated with virological response. Structural analyses were performed to assess the impact of mutations on protease conformation. RESULTS: UDS was successful in 127, 138 and 134 samples for protease, Gag and gp41, respectively (31% subtype B and 38% CRF02_AG). Overall, T4A and S37T mutations in protease were identified as being associated with VF (P = 0.02 and P = 0.005, respectively). Among CRF02_AG sequences, I72M and E21D mutations were associated with VF (P = 0.03 for both). They all induced some conformational changes of some protease side-chain residues located near mutated residues. In Gag, mutations associated with VF were G62D, N315H and Y441S (P = 0.005, P = 0.007 and P = 0.0003, respectively). All were localized outside Gag cleavage sites (G62D, matrix; N315H, capsid; and Y441S, p1). In gp41, the I270T mutation, localized in the cytoplasmic tail, was associated with VF (P = 0.003), and the I4L mutation, in the fusion peptide, was associated with virological success (P = 0.004). CONCLUSIONS: In this study, new baseline substitutions in Gag, protease and g41, potentially impacting PI-based regimen outcome, were evidenced. Phenotypic analyses are required to confirm their role in the PI-resistance mechanism.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Perrier M, Castain L, Regad L, et al. HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen. J Antimicrob Chemother. 2019. PMID: 30768160. doi:10.1093/jac/dkz043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。